Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Letrozole in Asian Postmenopausal Women with ER+/HER2- Advanced Breast Cancer
NCT02297438Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Palbociclib + Letrozole with Placebo + Letrozole (2 arms). Primary endpoint: Progression-Free Survival Based on Investigator's Assessment up to 65 months. Started Mar 2015; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02297438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297438.